uniQure N.V. (NASDAQ:QURE) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday, August 9th. The firm presently has a $9.25 target price on the biotechnology company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 9.99% from the company’s previous close.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
QURE has been the subject of several other research reports. ValuEngine raised shares of uniQure N.V. from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Jefferies Group LLC reissued a “hold” rating and set a $8.00 target price on shares of uniQure N.V. in a report on Wednesday, April 12th. Oppenheimer Holdings, Inc. set a $17.00 price objective on shares of uniQure N.V. and gave the company a “buy” rating in a report on Tuesday, May 16th. Cowen and Company reaffirmed a “buy” rating on shares of uniQure N.V. in a report on Wednesday, May 24th. Finally, Chardan Capital set a $13.00 price objective on shares of uniQure N.V. and gave the company a “buy” rating in a report on Sunday, July 23rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $15.04.
uniQure N.V. (NASDAQ:QURE) traded down 3.78% during midday trading on Wednesday, hitting $8.41. The stock had a trading volume of 35,910 shares. uniQure N.V. has a 52-week low of $4.72 and a 52-week high of $9.15. The firm’s market capitalization is $214.96 million. The firm has a 50-day moving average of $7.71 and a 200 day moving average of $6.20.
uniQure N.V. (NASDAQ:QURE) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.05. uniQure N.V. had a negative return on equity of 135.97% and a negative net margin of 203.99%. The business had revenue of $4.94 million for the quarter, compared to analysts’ expectations of $2.92 million. On average, equities analysts forecast that uniQure N.V. will post ($3.04) EPS for the current year.
WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.com-unik.info/2017/08/19/uniqure-n-v-nasdaqqure-upgraded-to-hold-at-zacks-investment-research-updated.html.
In other news, insider Harald Petry sold 58,075 shares of the business’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $6.01, for a total transaction of $349,030.75. Following the completion of the sale, the insider now owns 155 shares of the company’s stock, valued at $931.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 173,460 shares of company stock valued at $1,042,986 in the last ninety days. 0.64% of the stock is owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Oxford Asset Management bought a new stake in uniQure N.V. during the first quarter worth approximately $100,000. Mangrove Partners bought a new stake in uniQure N.V. during the second quarter worth approximately $247,000. JPMorgan Chase & Co. boosted its stake in uniQure N.V. by 50.5% in the first quarter. JPMorgan Chase & Co. now owns 43,822 shares of the biotechnology company’s stock worth $253,000 after buying an additional 14,702 shares in the last quarter. Weiss Multi Strategy Advisers LLC boosted its stake in uniQure N.V. by 266.7% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 55,000 shares of the biotechnology company’s stock worth $318,000 after buying an additional 40,000 shares in the last quarter. Finally, Paloma Partners Management Co boosted its stake in uniQure N.V. by 717.7% in the first quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock worth $491,000 after buying an additional 74,605 shares in the last quarter. 29.00% of the stock is owned by institutional investors and hedge funds.
About uniQure N.V.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about uniQure N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for uniQure N.V. and related companies.